期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

度洛西汀治疗糖尿病性神经痛56例临床疗效观察 被引量：5

暂未订购
导出
摘要 目的观察度洛西汀对糖尿病性神经痛(DPNP)的疗效及不良反应。方法对112例DPNP患者随机分为度洛西汀治疗组和加巴喷丁对照组,同时进行积极血糖控制和营养神经治疗,测定并比较治疗前、治疗后1、2、3、4周末的空腹血糖和餐后2小时血糖,并采用视觉模拟评分法(VAS)评价两种方法对疼痛的疗效并记录不良反应。结果 2组治疗前、治疗后1、2、3、4周空腹血糖和餐后2小时血糖均无显著性差异(均P>0.05);治疗3周及4周时治疗组疼痛程度评分(VAS)明显低于对照组(P<0.05);治疗4周后疼痛缓解率治疗组(94.6%)高于对照组(80.4%)(P<0.05);2组不良反应发生率无显著性差异(P>0.05)。结论度洛西汀治疗DPNP疗效确切,不良反应少,服药依从性佳,是治疗DPNP较理想的药物。
作者 陈文斌 汤义平 赵群峰 张丽霞
机构地区 台州市第二人民医院
出处 《浙江实用医学》 2013年第3期165-166,171,共3页 Zhejiang Practical Medicine
关键词 糖尿病性神经痛 度洛西汀 加巴喷丁
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献10

  • 1刘国凯,黄宇光,罗爱伦.加巴喷丁用于神经病理性疼痛治疗的研究进展[J].中国临床药理学与治疗学,2003,8(3):241-244. 被引量：45
  • 2Snow S, Kirwan J R. Visual analogue scales: a source of error. AnnRheum Dis, 1988,47(6) : 526.
  • 3马佳明,姚鹏,兰培丽,丁远远,王志斌.盐酸羟考酮缓释片联合普瑞巴林治疗糖尿病性神经痛的临床观察[J].实用药物与临床,2012,15(5):262-264. 被引量：19
  • 4Van Acker K,Bouhassira D,De Bacquer D, et al.Prevalence and im-pact on quality of life of peripheral neuropathy with or without neuro-pathic pain in type 1 and type 2 diabetic patients attending hospitaloutpatients clinics. Diabetes Metab,2009,35 (3): 206.
  • 5Ziegler D, Pritchett Y L, Wang F, et al. Impact of disease characteris-tics on the efficacy of duloxetine in diabetic peripheral neuropathicpain. Diabetes Care,2007,30(3) :664.
  • 6Wernicke J F,Pritchett Y L, Souza D N,et al. Arandomized controlledtrial of duloxetine in diabetic peripheral neuropathic pain. Neurology,2006,67(8):1411.
  • 7Coldstein D J, Lu Y, Detke M J, et al. Duloxetine vs placebo in pa-tients with painful diabetic neuropathy. Pain, 2005,116(1 - 2) : 109.
  • 8Renk,Dubner R. Descending modulation in persistent pain: an update.Pain, 2002,100(1-2):1.
  • 9Perahia D G, Pritchett Y L, Desaiah D,et al. Efficacy of duloxetine inpainful symptoms: an analgesic or antidepressant effect. Int Clin Psy-chopharmacol, 2006,21(6):311.
  • 10Raskin J, Pritchett Y L, Wang F, et al. A double - blind, randomizedmulticenter trial comparing duloxetine with placebo in the managementof diabetic peripheral neuropathic pain.Pain Med,2005,6(5) :346.

二级参考文献25

  • 1[1]Laird MA. Use of gabapentin in the treatment of neuropathic pain[J]. Ann pharmacother, 2000;34:802-7
  • 2[2]Jones DL. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperlgesia[J]. Brain Res, 1998;810:93-9
  • 3[3]Chen SR. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats[J]. Anesthesiology, 2000;92:500-6
  • 4[4]Rosenberg JM. The effect of gabapentin on neuropathic pain[J]. Clin J Pain, 1997;13:251-5
  • 5[5]Wiffen P. Anticonvulsant drugs for acute and chronic pain[DB/CD]. Cochrane Database System Review, 2000;3:001133
  • 6[6]Dallochio C. Gabapentin vs Amitriptyline in painful diabetic neuropathy. An open-label pilot study[J]. J Pain Symptom Manage, 2000;20:280-5
  • 7[7]Rowbotham M. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial[J]. J Am Medl Assoc, 1998;280:1837-42
  • 8[8]Caraceni A. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain[J]. J Pain Symptom Manage, 1999;17:441-2
  • 9[9]Devulder J. Gabapentin for pain control in cancer patients wound dressing care[J]. J Pain Symptom Manage, 2001;22:622-6
  • 10[10]Solaro C. Low-dose gabapentin combined with either lamotrigine or carbemazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis[J]. Eur J Neurol, 2000;44:45-8

共引文献62

同被引文献41

  • 1周欣,李圣华,李军荣.加巴喷丁治疗糖尿病性神经痛的临床研究[J].黑龙江医药,2012,25(5):722-724. 被引量：1
  • 2Tremont-Lukats IW, Meg C, BackonjaMM. Anticonvulsants :or neuropathic pain syndromes: mechanisms of action andplace in therapy[J]. Drugs,2000,60(5)1 029- 1 052.
  • 3Snow S,Kirwan J R. Visual analogue scales:a source of error [J]. Ann Rheum Dis,1988,47(6) :526-527.
  • 4Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspec- tives[J]. Pain,2006,7(12) :892-900.
  • 5Ziegler D, Pritchett YL, Wang F, et al. Impact of disease char- acteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain[J]. Diabetes Care,2007,30(3) :664-669.
  • 6Ziegler D. Management of painful diabetic neuropathy., what is new or in the pipeline for 2007[J]. Curr Diab Rep,2007,7(6) : 409-415.
  • 7Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management [J]. Anaesthesia, 2002,57 (5) : 451-462.
  • 8Bennett MI,Simpson KH. Gabapentin in the treatment of neu- ropathic pain[J]. Palliat Med, 2004,18(1) : 5-11.
  • 9宣丽萍.加巴喷丁治疗糖尿病神经病变性疼痛的疗效安全性[J].现代中西医结合杂志,2008,17(2):194-195. 被引量：5
  • 10Nakayama M,Nakamura J,Hamada Y,et al.Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy[J].Diabetes Care,2001,24(6):1093-1098.

引证文献5

二级引证文献21

浙江实用医学
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部